BioAtla Inc. (NASDAQ: BCAB) Stock Information | RedChip

BioAtla Inc. (NASDAQ: BCAB) Listen to this Section


$1.89
+0.2100 ( +12.50% ) 5.0M

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Market Data


Open


$1.89

Previous close


$1.68

Volume


5.0M

Market cap


$90.87M

Day range


$1.71 - $2.13

52 week range


$1.14 - $4.02

Insider Ownership Transactions

Total Amount Purchased: -104,506.00 | $ -197,516.34

Date Type Amount Purchased Purchaser
2024-08-01 Sale -572.00 Sievers Eric
2024-08-01 Sale -2181.00 Smith Scott Andrew
2024-07-01 Sale -572.00 Sievers Eric
2024-07-01 Sale -2181.00 Smith Scott Andrew
2024-06-14 Sale -16500.00 GRAY MARY ANN
2024-06-14 Sale -16500.00 Smith Scott Andrew
2024-06-14 Sale -16500.00 STEINMAN LAWRENCE
2024-06-14 Sale -16500.00 Williams Eddie
2024-06-14 Sale -16500.00 Moran Susan
2024-06-14 Sale -16500.00 MCBRINN SYLVIA

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 57 Aug 08, 2024
8-k 8K-related 12 Aug 08, 2024
4 Insider transactions 1 Aug 01, 2024
4 Insider transactions 1 Aug 01, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jul 01, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.